SCHWARZ & PARTNER
PATENTANWÄLTE
EUROPEAN PATENT AND TRADEMARK ATTORNEYS

Verified
By: DPeterson On: 05 Mar 2021

DIPL.-ING. HARALD NEMEC
DIPL.-ING. HERWIG MARGOTTI
MAG. DR. ANDREAS VÖGELE
DIPL.-ING. HARALD RÖGGLA
DIPL.-ING. DR. ANDREAS PFÖSTL
PHILIPP GRUBER, MSC ETH
DI DR. JOHANNES GALL-SCHUHMANN
DR. ALBIN SCHWARZ (OF COUNSEL)

WIPPLINGERSTRASSE 30
A-1010 WIEN
TEL: +43 1-533 18 50
FAX: +43 1-533 18 55
E-MAIL: OFFICE@KOPAS.AT

VIA EMAIL ONLY

DOCKETED
Atty JMG File# 15257.20B.5
By Jaclyn Boone On 04 Mar 2021
Action ***
Response Due ***
Submit IDR - Was POA sent?

Workman Nydegger
1000 Eagle Gate Tower
60 East South Temple
Salt Lake City 84111
USA

Email: docketing@WNLaw.com; jguynn@wnlaw.com; teller@wnlaw.com

Vienna, March 03, 2021

European Patent Application No. 18929441.6 (National Phase of PCT/US2018/059712)

Title:	*Compositions and methods for treating sexual dysfunction and enhancing sexual response and pleasure*
Applicant:	ILYLT, LLC
Your Ref:	15257.20b.5
Our Ref:	28205-WOEP /AV/CM

Dear Madam/Sir,

please be informed that the regional EP-phase of the above mentioned International Application has been entered for all designated countries on **March 02, 2021**. The European application has been allotted the official file number

18929441.6

and the filing date of the International Application, i.e.

November 07, 2018.

Enclosed please find one copy each of our petition (Entry into the European phase), of the Acknowledgement of Receipt, of the new set of claims as filed as well as of our debit note for services rendered. The examination fee was already due.

Provisional protection for the subject claimed is available, if a translation of the claims is published in the respective EP-Contracting State. If your client seeks provisional protections in one of the Contracting States please inform us accordingly.

Please let us also know in case your client wishes to expedite the examination procedure (no official charge; service charge EUR 80,--).

The next annuity fee to be paid is due on

November 30, 2021

As noted in your order letter, we will not be responsible for payment of annuity fees and therefore we have **not** entered this case into our records for annuity surveillance. In case you want us to pay annuities, please send your timely instructions.

We thank you very much for entrusting us this case.

Yours sincerely,

Dr. Andreas Vögele
Patent Attorney
(Electronically submitted)

Enclosures
Acknowledgment of Receipt
Request for Entering the EP Phase
New set of claims (clean and track mode)
Debit Note

Europäisches Patentamt
European Patent Office
Office européen des brevets

Acknowledgement of receipt

We hereby acknowledge receipt of the form for entry into the European phase (EPO as designated or elected Office) as follows:

Submission number	9555247
PCT application number	PCT/US2018/059712
EP application number	18929441.6
Date of receipt	02 March 2021
Receiving Office	European Patent Office, The Hague
Your reference	28205-WOEP
Applicant	
Country	

Documents submitted	package-data.xml application-body.xml AMSPECEPO-1.pdf\28205-WOEP amended claims.pdf (3 p.)	ep-euro-pct.xml epf1200.pdf (5 p.) CLMS-HWA.pdf\28205-WOEP amended claims (marked).pdf (6 p.)

Submitted by	CN=Andreas Vögele 22817
Method of submission	Online
Date and time receipt generated	02 March 2021, 11:49 (CET)
Message Digest	DD:04:27:F9:F7:A0:8C:39:87:C8:1E:A9:78:BA:CF:36:BC:1B:19:D3

/European Patent Office/

Europäisches Patentamt
European Patent Office
Office européen des brevets

Entry into the European phase (EPO as designated or elected Office)

To the European Patent Office

European application number	EP18929441.6
PCT application number	PCT/US2018/059712
PCT publication number	WO2020032988
Applicant's or representative's reference	28205-WOEP
International Filing Date	07.11.2018
International Searching Authority (ISA)	US
International Preliminary Examining Authority (IPEA)	not applicable

1. Applicant

Indications concerning the applicant(s) are contained in the international publication or were recorded by the International Bureau after the international publication. ☒

Changes which have not yet been recorded by the International Bureau are set out here: ☐

2. Representative

Representative 1

Representative or association of representatives to be listed in the Register of European Patents and to whom communications are to be notified

Name: Schwarz & Partner Patentanwälte OG

Association No.: 358

Address of place of business: Wipplingerstrasse 30
1010 Wien,
Austria

Telephone: +43 1 533 18 50

Fax: +43 1 533 18 55

E-mail: office@kopas.at

Representative 2

Name: VÖGELE, Herr Andreas

3. Authorisation

Representative 1

An individual authorisation is attached. ☐

A general authorisation has been registered under No: ☐

A general authorisation has been filed, but not yet registered. ☐

The authorisation filed with the EPO as PCT receiving Office expressly includes the European phase. ☐

Representative 2

An individual authorisation is attached. ☐

A general authorisation has been registered under No: ☐

A general authorisation has been filed, but not yet registered. ☐

The authorisation filed with the EPO as PCT receiving Office expressly includes the European phase. ☐

4. Request for examination

Examination of the application under Art. 94 EPC is hereby requested. The examination fee is being (has been, will be) paid. ☒

Request for examination in an admissible non-EPO language: ☐

The/Each applicant hereby declares that he is an entity or a natural person under Rule 6(4) EPC. ☐

5. Copies

Additional copies of the documents cited in the supplementary European search report are requested.	☐
Number of additional sets of copies	

6. Documents intended for proceedings before the EPO

Number of claims on entry into the European phase:	15
6.1 Proceedings before the EPO as designated Office (PCT I) are to be based on the following documents	
the application documents published by the International Bureau; where the publication includes a set of claims amended under Article 19 PCT, the latter replaces the originally filed claims	☐
unless replaced by the amendments attached.	☒
Comments on the international preliminary examination report established by the EPO as the International Preliminary Examining Authority and/or observations are attached.	☐
Where necessary, further details should be attached as "Other documents"	
6.2 Proceedings before the EPO as elected Office (PCT II) are to be based on the following documents:	
the documents on which the international preliminary examination report is based, including any annexes	☐
unless replaced by the amendments attached.	☐
comments on the international preliminary examination report established by the EPO as the International Preliminary Examining Authority and/or observations are enclosed.	☐
Where necessary, further details should be attached as "Other documents"	
If the EPO as International Preliminary Examining Authority has been supplied with test reports, these may be used as the basis of proceedings before the EPO.	☐
6.3 A copy of the results of the search carried out by the authority with which the previous application(s) whose priority is claimed was (were) filed is attached (R. 141(1) EPC).	☐

7. Translations

Translations in one of the official languages of the EPO (English, French, German) are attached as crossed below:	☐
** In proceedings before the EPO as designated or elected Office (PCT I + II):*	
7.1 Translation of the international application (description, claims, any text in the drawings) as originally filed, of the abstract as published and of any indication under Rule 13bis.3 and 13bis.4 PCT regarding biological material	☐
7.2 Translation of the priority application(s) (to be filed only at the EPO's request, Rule 53(3) EPC)	☐
7.3 It is hereby declared that the international application as originally filed is a complete translation of the previous application (Rule 53(3) EPC)	☐
** In addition, in proceedings before the EPO as designated Office (PCT I):*	
7.4 Translation of amended claims and any statement under Art. 19 PCT, if the claims as amended are to form the basis for the proceedings before the EPO (see Section 6).	☐
** In addition, in proceedings before the EPO as elected Office (PCT II):*	
7.5 Translation of any annexes to the international preliminary examination report	☐

8. Biological material

The invention uses and/or relates to biological material deposited under Rule 31 EPC.	☐
The particulars referred to in Rule 31(1)(c) EPC (if not yet known, the depositary institution and the identification reference(s)) [number, symbols, etc.] of the depositor) are given in the international publication or in the translation submitted in Section 7 on:	☐
page(s) / line(s)	
The receipt(s) of deposit issued by the depositary institution	
is (are) enclosed.	☐
will be filed later.	☐

Waiver of the right to an undertaking from the requester pursuant to Rule 33(2) EPC attached. ☐

9. Nucleotide and amino acid sequences

The international application discloses nucleotide and/or amino acid sequences. ☐

9.1 The sequence listing was filed under Rule 5.2(a) PCT, or furnished to the EPO as ISA under Rule 13ter.1(a) PCT, or is otherwise available to the EPO, in computer-readable format in accordance with WIPO ST.25. ☐

9.2

The sequence listing is attached in computer-readable format in accordance with WIPO Standard ST.25 (Rule 163(3) EPC) ☐

The sequence listing does not include matter which goes beyond the content of the application as filed. ☐

10. Designation of contracting states

All the contracting states party to the EPC at the time of filing of the international patent application and designated in the international application are deemed to be designated (see Article 79(1) EPC). ☒

11. Extension/Validation

This application is deemed to be a request to extend the effects of the European patent application and the European patent granted in respect of it to all non-contracting states to the EPC designated in the international application with which extension or validation agreements were in force on the date on which the application was filed. However, the request is deemed withdrawn if the extension fee or the validation fee, whichever is applicable, is not paid within the prescribed time limit. ☐

11.1 It is intended to pay the extension fee(s) for the following state(s):

11.2 It is intended to pay the validation fee(s) for the following state(s):

Note: Under the automatic debiting procedure, extension and/or validation fees will be debited only for states indicated here unless the EPO is instructed otherwise before expiry of the period for payment.

12. Acceleration of procedure

12.1 Early processing

Early processing of the application pursuant to Article 23(2) / 40(2) PCT is hereby requested (“early entry into the European phase”) ☐

12.2 Waivers

The applicant waives his right to the communication under Rules 161(1) or (2) and 162 EPC. ☐

The applicant waives his right to be asked under Rule 70(2) EPC whether he wishes to proceed further with the application. ☐

13. List of enclosed documents

	Description of document	Original file name	Assigned file name
1	Combined Amendments	28205-WOEP amended claims.pdf	AMSPECEPO-1.pdf
2	Amended claims with annotations	28205-WOEP amended claims (marked).pdf	CLMS-HWA.pdf

14. Method of payment: Debit from deposit account ☒

Currency: EUR

The European Patent Office is hereby authorised, to debit from the deposit account with the EPO any fees and costs indicated on the fees page.

Deposit account number: 28010054

Account holder: Schwarz & Partner Patentanwälte OG

15. Any refunds should be made to the following EPO deposit account: ☒

Number and account holder: Schwarz & Partner Patentanwälte OG, 28010054

16. Fees

	Factor/reduction applied	Fee schedule	Amount to be paid

16-1	002 Fee for a European search - Applications filed on/after 01.07.2005	1	1 350.00	1 350.00
16-2	005e Designation fee - For all contracting States designated for applications filed on/after 01.04.2009	1	610.00	610.00
16-3	006 Examination fee - For applications filed on/after 01.07.2005	1	1 700.00	1 700.00
16-4	015 Claims fee - For the 16th to the 50th claim	0	245.00	0.00
16-5	15e Claims fee - For the 51st and each subsequent claim	0	610.00	0.00
16-6	020 Filing fee - entry EP phase - online	1	125.00	125.00
16-7	033 Renewal fee for the 3rd year	1	490.00	490.00
16-8	520 Additional filing fee for the 36th and each subsequent page - entry into EP phase	0	16.00	0.00
	Total:		**EUR**	**4 275.00**

17. Annotations

18. Signature(s) of applicant(s) or representative

Place:	**Vienna**
Date:	**02 March 2021**
Signed by:	**Andreas Vögele 22817**
Representative name:	**Andreas VÖGELE**
Capacity:	**(Representative)**

Table for section 6 of Form 1200.3

In accordance with the Notice from the European Patent Office dated 26 January 2009 concerning the 2009 fee structure (OJ EPO 2009, 118, and Guidelines for Examination in the EPO, April 2009, A-III, 13.2), the amount of the additional fee (Art. 2, item 1a, Rules relating to Fees) for the pages of this European patent application is calculated as follows:

Documents intended for proceedings before the EPO (R. 159 (1) (b) EPC) and for calculating the additional fee (Art. 2, item 1a, RFees):

		Page(s) from ... to ...	Number of pages
Description:	International application as published	1-22	22
Claims:	Amendments filed on entry into European phase	1-3	3
Drawings:	NONE	-	-
Abstract:	Default count: one page		1
Total number of pages			26
Fee-exempt pages (Art. 2, item 1a, RFees)			-35
Number of pages to be paid for			0
			(x 16 EUR per page)
Total amount payable		EUR	0

CLAIMS

1. A pharmaceutical composition for treating sexual dysfunction in a human, comprising one or more dosage forms configured to deliver:

a cannabinoid component comprised of at least one of 5 mg to 500 mg of tetrahydrocannabinol (THC) or 5 mg to 500 mg of cannabidiol (CBD); and

a therapeutically effective amount of a sexual response enhancing component selected from the group consisting of sildenafil, tadalafil, and vardenafil.

~~2. The pharmaceutical composition of claim 1, wherein the cannabinoid component further comprises at least one of cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabigerol (CBG), dronabinol, nabilone, a derivative of THC, or a derivative of CBD.~~

~~3. The pharmaceutical composition of claim 1 or 2, wherein at least a portion of the cannabinoid component is obtained from plant parts of one or more plants selected from *Cannabis sativa*, *Cannabis indica*, and hybrids thereof.~~

~~4. The pharmaceutical composition of any one of claims 1 to 3, wherein the one or more dosage forms are configured to deliver 7.5 mg to 450 mg, or 10 mg to 400 mg, or 15 mg to 350 mg, or 20 mg to 300, or 25 mg to 250 mg of THC, or 35 mg to 200 mg of THC.~~

~~5. The pharmaceutical composition of any one of claims 1 to 4, wherein the one or more dosage forms are configured to deliver 7.5 mg to 450 mg, or 10 mg to 400 mg, or 15 mg to 350 mg, or 20 mg to 300, or 25 mg to 250 mg of THC, or 35 mg to 200 mg of CBD.~~

~~6.~~2. The pharmaceutical composition of claim 1 ~~any one of claims 1 to 5~~, wherein the one or more dosage forms comprise a tablet, ~~or~~ capsule, or suppository.

~~7. The pharmaceutical composition of any one of claims 1 to 5, wherein the one or more dosage forms comprise a suppository.~~

~~8. The pharmaceutical composition of any one of claims 1 to 7, wherein the sexual response enhancing component is vardenafil.~~

~~9. The pharmaceutical composition of any one of claims 1 to 7, wherein the sexual response enhancing component is sildenafil.~~

~~10. The pharmaceutical composition of any one of claims 1 to 7, wherein the sexual response enhancing component is tadalafil.~~

~~11.~~3. An ingestible dosage form for enhancing sexual response and sensitivity in a human, comprising:

an ingestible cannabinoid component comprising at least one of 5 mg to 500 mg of tetrahydrocannabinol (THC) or 5 mg to 500 mg of cannabidiol (CBD); and

a tablet or capsule that contains a sexual response enhancing component selected from a therapeutically effective amount of sildenafil, tadalafil, or vardenafil ~~in~~ and/or at least 1 g, such as at least 2 g, of an herbal supplement comprising one or more of L-arginine, L-citrulline, yahimbe root, ginseng (*e.g.*, Korean red ginsing), ginkgo biloba, horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, and/or damiana.

~~12. The ingestible dosage form of claim 11, wherein the ingestible cannabinoid component is a tablet or capsule.~~

~~13.~~4. The ingestible dosage form of claim 3 ~~11~~, wherein the ingestible cannabinoid component is selected from the group consisting of tablet, capsule, oral drops, lozenges, lollipops, food preparations, such as brownies, cookies, or chocolates, chews, gum drops, soft candies, hard candies, and liquid shots.

~~14.~~5. A composition for enhancing sexual response and sensitivity in a human, comprising:

a topical cannabinoid dosage form comprising at least one 5 mg to 500 mg of tetrahydrocannabinol (THC) or 5 mg to about 500 mg of cannabidiol (CBD); and

a tablet or capsule that contains a sexual response enhancing component selected from a therapeutically effective amount of sildenafil, tadalafil, or vardenafil in and/or at least 1 g, such as at least 2 g, of an herbal supplement comprising one or more of L-arginine, L-citrulline, yahimbe root, ginseng (*e.g.*, Korean red ginsing), ginkgo biloba,

horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, and/or damiana.

~~15.~~6. The composition of claim 5 ~~14~~, wherein the topical cannabinoid dosage form is selected from the group consisting of massage oils, lotions, gels, creams, lubricants, genital sprays, vaginal patch, vaginal suppository, and anal suppository.

~~16.~~7. A composition for enhancing sexual response and sensitivity in a human, comprising:

a vaporizable and inhalable cannabinoid dosage form configured to provide at least one of a dose of 5 mg to 500 mg of tetrahydrocannabinol (THC) or a dose of 5 mg to 500 mg of cannabidiol (CBD); and

a tablet, capsule, or topical dosage form that contains a sexual response enhancing component selected from a therapeutically effective amount of sildenafil, tadalafil, or vardenafil in and/or at least 1 g, such as at least 2 g, of an herbal supplement comprising one or more of L-arginine, L-citrulline, yahimbe root, ginseng (*e.g.*, Korean red ginsing), ginkgo biloba, horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, and/or damiana.

~~17.~~8. The composition of claim 7 ~~16~~, wherein the vaporizable and inhalable cannabinoid dosage form is formulated for vaporization and inhalation using a heat vaporizer or a nebulizer.

~~18. The composition of claim 16, wherein the vaporizable and inhalable cannabinoid dosage form is formulated for vaporization and inhalation using a nebulizer.~~

~~19.~~9. A ~~method of~~ composition for treating sexual dysfunction and/or enhancing sexual response and sensitivity in a human, comprising:

a cannabinoid configured to be administered ~~administering~~ by ingestion, inhalation, or topically, ~~a~~ the cannabinoid comprising at least one of tetrahydrocannabinol (THC) or cannabidiol (CBD); and

a sexual response component configured to be administered ~~administering~~ by ingestion and including an effective amount of a sexual response component selected

from the group consisting of sildenafil, tadalafil, vardenafil, herbal supplement, and combinations thereof.

~~20.~~10. The ~~method~~ composition of claim 9 ~~19~~, wherein the cannabinoid comprises 5-500 mg, or 7.5-450 mg, or 10-400 mg, or 15-350 mg, or 20-300 mg, or 25-250 mg of THC and/or 5-500 mg, or 7.5-450 mg, or 10-400 mg, or 15-350 mg, or 20-300 mg, or 25-250 mg of CBD.

~~21. The method of claim 19 or 20, wherein the cannabinoid comprises 5-500 mg, or 7.5-450 mg, or 10-400 mg, or 15-350 mg, or 20-300 mg, or 25-250 mg of CBD.~~

~~22. The method of at least one of claims 19 to 21, wherein the cannabinoid comprises THC, CBD, and at least one of cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabigerol (CBG), dronabinol, nabilone, a derivative of THC, or a derivative of CBD.~~

~~23.~~11. The ~~method~~ composition of claim 9 or 10 at least one of claims 19 to 22, wherein the cannabinoid is configured to be administered as an infused edible, oral drop, liquid shot, capsule, or tablet.

~~24. The method of at least one of claims 19 to 22, wherein the cannabinoid is administered as an oral drop or liquid shot.~~

~~25.~~12. The ~~method~~ composition of claim 9 or 10 ~~at least one of claims 19 to 22~~, wherein the cannabinoid is configured to be administered by inhalation of a heat vaporized cannabis extract.

~~26. The method of at least one of claims 19 to 22, wherein the cannabinoid is administered as a capsule or tablet.~~

~~27.~~13. The ~~method~~ composition of claim 9 or 10 ~~at least one of claims 19 to 22~~, wherein the cannabinoid is administered topically as an oil, lotion, gel, cream, lubricant, genital spray, vaginal patch, vaginal suppository, or anal suppository.

~~28. The method of at least one of claims 19 to 27, wherein the sexual response component is administered as a capsule or tablet.~~

~~29. The method of at least one of claims 19 to 28, wherein the sexual response component is selected from the group consisting of sildenafil, tadalafil, and vardenafil.~~

~~30.~~14. The ~~method~~ composition of any ~~at least~~ one of claims 9 to 13 ~~19 to 28~~, wherein the sexual response component is an herbal supplement selected from the group consisting of L-arginine, L-citrulline, yahimbe root, ginseng (*e.g.*, Korean red ginsing), ginkgo biloba, horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, damiana, and combinations thereof.

~~31.~~15. A ~~method of~~ composition for treating sexual dysfunction and/or enhancing sexual response and sensitivity in a human, comprising:

~~administering~~ a ~~cannabinoid via~~ tablet or capsule~~, the cannabis extract~~ comprising at least one of tetrahydrocannabinol (THC) or cannabidiol (CBD); and

~~administering via~~ a tablet or capsule comprising an effective amount of a sexual response component selected from the group consisting of sildenafil, tadalafil, vardenafil, L-arginine, herbal supplement, and combinations thereof.

~~32. The method of claim 31, wherein the sexual response component is selected from the group consisting of sildenafil, tadalifil, and vardenafil.~~

~~33. A method of treating sexual dysfunction and/or enhancing sexual response and sensitivity in a human, comprising:~~

~~administering a cannabinoid by ingestion of a tablet, a capsule, an infused edible, or liquid shot, the cannabis extract comprising at least one of tetrahydrocannabinol (THC) or cannabidiol (CBD); and~~

~~administering by ingestion an effective amount of a pharmaceutical selected from the group consisting of sildenafil, tadalafil, and vardenafil.~~

~~34. The method of claim 33, wherein the pharmaceutical comprises sildenafil.~~

~~35. The method of claim 33, wherein the pharmaceutical comprises tadalafil.~~

~~36. The method of claim 33, wherein the pharmaceutical comprises vardenafil.~~

CLAIMS

1. A pharmaceutical composition for treating sexual dysfunction in a human, comprising one or more dosage forms configured to deliver:

a cannabinoid component comprised of at least one of 5 mg to 500 mg of tetrahydrocannabinol (THC) or 5 mg to 500 mg of cannabidiol (CBD); and

a therapeutically effective amount of a sexual response enhancing component selected from the group consisting of sildenafil, tadalafil, and vardenafil.

2. The pharmaceutical composition of claim 1, wherein the one or more dosage forms comprise a tablet, capsule, or suppository.

3. An ingestible dosage form for enhancing sexual response and sensitivity in a human, comprising:

an ingestible cannabinoid component comprising at least one of 5 mg to 500 mg of tetrahydrocannabinol (THC) or 5 mg to 500 mg of cannabidiol (CBD); and

a tablet or capsule that contains a sexual response enhancing component selected from a therapeutically effective amount of sildenafil, tadalafil, or vardenafil and/or at least 1 g, such as at least 2 g, of an herbal supplement comprising one or more of L-arginine, L-citrulline, yahimbe root, ginseng (*e.g.*, Korean red ginsing), ginkgo biloba, horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, and/or damiana.

4. The ingestible dosage form of claim 3, wherein the ingestible cannabinoid component is selected from the group consisting of tablet, capsule, oral drops, lozenges, lollipops, food preparations, such as brownies, cookies, or chocolates, chews, gum drops, soft candies, hard candies, and liquid shots.

5. A composition for enhancing sexual response and sensitivity in a human, comprising:

a topical cannabinoid dosage form comprising at least one 5 mg to 500 mg of tetrahydrocannabinol (THC) or 5 mg to about 500 mg of cannabidiol (CBD); and

a tablet or capsule that contains a sexual response enhancing component selected from a therapeutically effective amount of sildenafil, tadalafil, or vardenafil in and/or at

least 1 g, such as at least 2 g, of an herbal supplement comprising one or more of L-arginine, L-citrulline, yahimbe root, ginseng (*e.g.*, Korean red ginsing), ginkgo biloba, horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, and/or damiana.

6. The composition of claim 5, wherein the topical cannabinoid dosage form is selected from the group consisting of massage oils, lotions, gels, creams, lubricants, genital sprays, vaginal patch, vaginal suppository, and anal suppository.

7. A composition for enhancing sexual response and sensitivity in a human, comprising:

a vaporizable and inhalable cannabinoid dosage form configured to provide at least one of a dose of 5 mg to 500 mg of tetrahydrocannabinol (THC) or a dose of 5 mg to 500 mg of cannabidiol (CBD); and

a tablet, capsule, or topical dosage form that contains a sexual response enhancing component selected from a therapeutically effective amount of sildenafil, tadalafil, or vardenafil in and/or at least 1 g, such as at least 2 g, of an herbal supplement comprising one or more of L-arginine, L-citrulline, yahimbe root, ginseng (*e.g.*, Korean red ginsing), ginkgo biloba, horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, and/or damiana.

8. The composition of claim 7, wherein the vaporizable and inhalable cannabinoid dosage form is formulated for vaporization and inhalation using a heat vaporizer or a nebulizer.

9. A composition for treating sexual dysfunction and/or enhancing sexual response and sensitivity in a human, comprising:

a cannabinoid configured to be administered by ingestion, inhalation, or topically, the cannabinoid comprising at least one of tetrahydrocannabinol (THC) or cannabidiol (CBD); and

a sexual response component configured to be administered by ingestion and including an effective amount of a sexual response component selected from the group consisting of sildenafil, tadalafil, vardenafil, herbal supplement, and combinations thereof.

10. The composition of claim 9, wherein the cannabinoid comprises 5-500 mg, or 7.5-450 mg, or 10-400 mg, or 15-350 mg, or 20-300 mg, or 25-250 mg of THC and/or 5-500 mg, or 7.5-450 mg, or 10-400 mg, or 15-350 mg, or 20-300 mg, or 25-250 mg of CBD.

11. The composition of claim 9 or 10 at least one of claims 19 to 22, wherein the cannabinoid is configured to be administered as an infused edible, oral drop, liquid shot, capsule, or tablet.

12. The composition of claim 9 or 10, wherein the cannabinoid is configured to be administered by inhalation of a heat vaporized cannabis extract.

13. The composition of claim 9 or 10, wherein the cannabinoid is administered topically as an oil, lotion, gel, cream, lubricant, genital spray, vaginal patch, vaginal suppository, or anal suppository.

14. The composition of any one of claims 9 to 13, wherein the sexual response component is an herbal supplement selected from the group consisting of L-arginine, L-citrulline, yahimbe root, ginseng (*e.g.*, Korean red ginsing), ginkgo biloba, horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, damiana, and combinations thereof.

15. A composition for treating sexual dysfunction and/or enhancing sexual response and sensitivity in a human, comprising:

a tablet or capsule comprising at least one of tetrahydrocannabinol (THC) or cannabidiol (CBD); and

a tablet or capsule comprising an effective amount of a sexual response component selected from the group consisting of sildenafil, tadalafil, vardenafil, L-arginine, herbal supplement, and combinations thereof.